$599

Zealand Establishes Boston Research Hub; Aardvark Pipeline on Hold; Rezolute Shares CHI Program Updates; Rivus New MASH Trial

A series of cardiometabolic-related news items has been observed by Zealand Pharma, Aardvark Therapeutics, Rezolute, and Rivus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here